Hollenberg N K
Brigham and Women's Hospital, Boston, MA 02115, USA.
Curr Opin Cardiol. 1996 Sep;11(5):457-63. doi: 10.1097/00001573-199609000-00002.
Although it has been recognized for almost 70 years that there is a substantial genetic component to the pathogenesis of hypertension, only recently have systematic efforts been made to identify the responsible genetically determined mechanisms. In the case of several rare syndromes, spectacular progress has been made in identifying the underlying molecular mechanisms responsible for the clinical expression. Glucocorticoid-suppressible aldosteronism and Liddle's syndrome, each inherited as an autosomal-dominant condition, complete the list. In the case of randomly selected patients and families with essential hypertension, inheritance involves many genes and progress has been far more modest. Probably the most promising lead has involved the genes governing the structure of angiotensinogen, the substrate in the renin reaction. Linkage has been established and confirmed. At the moment, however, neither the relation of the genetic abnormality to the underlying mechanisms, nor the contribution of this abnormality to hypertension in the individual patient, has been defined. We know less about other candidate genes, with the exception of studies that rigorously ruled out a contribution. The development of the concept of the "intermediate phenotype," a physiological feature that makes it possible to identify a homogeneous subpopulation, should help to sort out many of these issues. Unfortunately, the identification and characterization of intermediate phenotypes is substantially more difficult at the moment than are the genetic studies, and so progress is likely to be slow. The field is complicated by the reporting of claims made on the basis of small patient samples. In the case of polymorphisms in the angiotensin-converting enzyme gene as a risk factor for tissue injury, for example, substantial follow-up studies have systematically failed to confirm the original report, which was based on a small patient sample. The fact that the same DNA collection is likely to be examined many times for multiple gene candidates creates a setting in which type I errors are likely, and so we are likely to see many more examples. Caveat lector. Again, the development of relevant intermediate phenotypes will make the spurious association less likely.
尽管近70年来人们已经认识到高血压发病机制中存在大量遗传因素,但直到最近才开始系统地努力确定相关的遗传决定机制。在几种罕见综合征的研究中,已经在确定导致临床表现的潜在分子机制方面取得了显著进展。糖皮质激素可抑制性醛固酮增多症和利德尔综合征,均为常染色体显性遗传疾病,也在研究之列。对于随机选择的原发性高血压患者及其家族,遗传涉及多个基因,进展要小得多。可能最有前景的线索涉及控制血管紧张素原结构的基因,血管紧张素原是肾素反应中的底物。已经建立并证实了连锁关系。然而,目前遗传异常与潜在机制的关系,以及这种异常对个体患者高血压的影响均未明确。除了那些经过严格排除其作用的研究外,我们对其他候选基因了解更少。“中间表型”概念的发展,即一种有助于识别同质亚群的生理特征,应该有助于解决其中的许多问题。不幸的是,目前中间表型的识别和特征描述比基因研究要困难得多,因此进展可能会很缓慢。该领域因基于小样本患者得出的结论报告而变得复杂。例如,关于血管紧张素转换酶基因多态性作为组织损伤危险因素的报道,大量后续研究系统地未能证实基于小样本患者的原始报告。同一DNA样本可能会被多次检测多种基因候选物,这就增加了出现I型错误的可能性,因此我们可能会看到更多此类例子。读者需谨慎。同样,相关中间表型的发展将减少虚假关联的可能性。